AbbVie Inc. (ABBV)
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
Can This Dividend King Ever Hit $400 After This Major Fail?
Pharmaceutical giant AbbVie (NYSE:ABBV) has suffered a meltdown over the past week, with shares losing 15% of their value.
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
The drugmaker has convincingly laid to rest the biggest threat to its top line.
Final Trades: Bitcoin, Abbvie and Baker Hughes
The Investment Committee reveals their final trades for today.
2 Dividend Stocks to Buy Hand Over Fist in November
These companies have solid businesses and excellent dividend growth track records.
Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects
Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. AbbVie entered an option agreement with Aldeyra, potentially licensing reproxalap for global markets. Aldeyra conducted a Phase 3 trial, where reproxalap met its primary endpoint in DED patients.
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.
AbbVie's loss is Bristol Myers Squibb's gain - analyst
Recent trial failures over at pharma giant AbbVie Inc have created a window of opportunity for competitor Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP), is analysts at UBS are to be believed. AbbVie stock took a $38 billion hit on Monday after the company revealed that Phase 2 trials of its emraclidine schizophrenia treatment have failed to meet their primary endpoint objectives.
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY stock rises.
AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie's “pain” is Bristol Myers Squibb's “gain,” says Truist Securities analyst Srikripa Devarakonda.
Buy, Sell, Or Hold AbbVie Stock?
AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their primary goal. [1] Emraclidine was developed by Cerevel Therapeutics, which AbbVie acquired for around $9 billion earlier this year.
